Role of TNF-α in vascular dysfunction

Clinical Science

Volumn 116, Issue 3, 2009, Pages 219-230

  Zhang, Hanrui ^a,b   Park, Yoonjung ^a,b   Wu, Junxi ^a,b   Chen, Xiu Ping ^a,b   Lee, Sewon ^a,b   Yang, Jiyeon ^a,b   Dellsperger, Kevin C ^a   Zhang, Cuihua ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Inflammation; Macrovascular circulation; Microvascular circulation; Nitric oxide; Reactive oxygen species (ROS); Tumour Necrosis factor (TNF )

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; CERIVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; ETANERCEPT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; JANUS KINASE; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CARBOHYDRATE DIET; CYTOKINE PRODUCTION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VASCULAR DISEASE; AGING; ANIMAL; DRUG ANTAGONISM; FAT INTAKE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL; VASCULAR ENDOTHELIUM;

AGING; ANIMALS; DIETARY CARBOHYDRATES; DIETARY FATS; ENDOTHELIUM, VASCULAR; EXERCISE; HUMANS; LIPID METABOLISM; REACTIVE OXYGEN SPECIES; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 60549098432     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080196     Document Type: Review

References (122)

1. Guyton, A. C. and Hall, J. E. (1997) Human Physiology and Mechanism of Disease, 6th edn, Saunders, Philadelphia
2. Stenvinkel, P. (2001) Endothelial dysfunction and inflammation: is there a link? Nephrol. Dial. Transplant. 16, 1968-1971
3. Moncada, S., Palmer, R. M. and Higgs, E. A. (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-142
4. MacNaul, K. L. and Hutchinson, N. I. (1993) Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem. Biophys. Res. Commun. 196, 1330-1334
5. Zhang, J., Patel, J. M., Li, Y. D. and Block, E. R. (1997) Proinflammatory cytokines downregulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells. Res. Commun. Mol. Pathol. Pharmacol. 96, 71-87
6. Goodwin, B. L., Pendleton, L. C., Levy, M. M., Solomonson, L. P. and Eichler, D. C. (2007) Tumor necrosis factor-α reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 293, H1115-H1121
7. Xia, Z., Liu, M., Wu, Y. et al. (2006) N-acetylcysteine attenuates TNF-α-induced human vascular endothelial cell apoptosis and restores eNOS expression. Eur. J. Pharmacol. 550, 134-142
8. Seidel, M., Billert, H. and Kurpisz, M. (2006) Regulation of eNOS expression in HCAEC cell line treated with opioids and proinflammatory cytokines. Kardiol. Pol. 64, 153-158
9. Yoshizumi, M., Perrella, M. A., Burnett, Jr, J. C. and Lee, M. E. (1993) Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 73, 205-209
10. De Palma, C., Meacci, E., Perrotta, C., Bruni, P. and Clementi, E. (2006) Endothelial nitric oxide synthase activation by tumor necrosis factor α through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol. 26, 99-105
11. Zhong, L., You, J. and Sun, Q. (1999) The role of NF-κB in the TNF-α-induced endothelial cell apoptosis. Zhonghua Yixue Zazhi 79, 863-866
12. Bereta, J., Bereta, M., Allison, A. C., Kruger, P. B. and Koj, A. (1997) Inhibitory effect of di-catechol rooperol on VCAM-1 and iNOS expression in cytokine-stimulated endothelium. Life Sci. 60, 325-334
13. Jantzen, F., Koneman, S., Wolff, B. et al. (2007) Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J. Physiol. Pharmacol. 58, 503-514
14. db mice. Circulation 115, 245-254
15. Picchi, A., Gao, X., Belmadani, S. et al. (2006) Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 99, 69-77
16. Aoki, N., Siegfried, M. and Lefer, A. M. (1989) Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. Am. J. Physiol. 256, H1509-H1512
17. Ahmad, M., Zhang, Y., Papharalambus, C. and Alexander, R. W. (2002) Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-α stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22, 759-764
18. Zhang, C., Xu, X., Potter, B. J. et al. (2006) TNF-α contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 26, 475-480
19. Greenberg, S., Xie, J., Wang, Y. et al. (1993) Tumor necrosis factor-α inhibits endothelium-dependent relaxation. J. Appl. Physiol. 74, 2394-2403
20. Xie, L., Hattori, Y., Tume, N. and Gross, S. S. (2000) The preferred source of arginine for high-output nitric oxide synthesis in blood vessels. Semin. Perinatol. 24, 42-45
21. Goodwin, B. L., Solomonson, L. P. and Eichler, D. C. (2004) Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J. Biol. Chem. 279, 18353-18360
22. Hattori, Y., Campbell, E. B. and Gross, S. S. (1994) Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. Role in the regeneration or arginine for nitric oxide synthesis. J. Biol. Chem. 269, 9405-9408
23. Husson, A., Brasse-Lagnel, C., Fairand, A., Renouf, S. and Lavoinne, A. (2003) Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur. J. Biochem. 270, 1887-1899
24. Oyadomari, S., Gotoh, T., Aoyagi, K., Araki, E., Shichiri, M. and Mori, M. (2001) Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide 5, 252-260
25. Feletou, M. and Vanhoutte, P. M. (2006) Endothelial dysfunction: a multifaceted disorder. Am. J. Physiol. Heart Circ. Physiol. 291, H985-H1002
26. Fitzgerald, S. M., Kemp-Harper, B. K., Tare, M. and Parkington, H. C. (2005) Role of endothelium-derived hyperpolarizing factor in endothelial dysfunction during diabetes. Clin. Exp. Pharmacol. Physiol. 32, 482-487
27. De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H. and Vanhoutte, P. M. (2000) Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130, 963-974
28. Wimalasundera, R., Fexby, S., Regan, L., Thom, S. A. and Hughes, A. D. (2003) Effect of tumour necrosis factor-α and interleukin 1β on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br. J. Pharmacol. 138, 1285-1294
29. Gillham, J. C., Myers, J. E., Baker, P. N. and Taggart, M. J. (2008) TNF-α alters nitric oxide- and endothelium-derived hyperpolarizing factor-mediated vasodilatation in human omental arteries. Hypertens. Pregnancy 27, 29-38
30. Kessler, P., Popp, R., Busse, R. and Schini-Kerth, V. B. (1999) Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 99, 1878-1884
31. a Park, Y., Capobianco, S., Gao, X., Falck, J. R., Dellsperger, K. C. and Zhang, C. (2008) Role of EDHF in Type 2 diabetes-induced endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol., doi:10.1152/ ajpheart.01261.2007
32. De Martin, R., Hoeth, M., Hofer-Warbinek, R. and Schmid, J. A. (2000) The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 20, E83-E88
33. Ye, J., Wang, L., Zhang, X., Tantishaiyakul, V. and Rojanasakul, Y. (2003) Inhibition of TNF-α gene expression and bioactivity by site-specific transcription factor-binding oligonucleotides. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L386-L394
34. Sorescu, D. and Griendling, K. K. (2002) Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Failure 8, 132-140
35. Downey, J. M., Omar, B., Ooiwa, H. and McCord, J. (1991) Superoxide dismutase therapy for myocardial ischemia. Free Radical Res. Commun. 12-13, 703-720
36. Pritchard, Jr, K. A., Groszek, L., Smalley, D. M. et al. (1995) Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77, 510-518
37. Cai, H. and Harrison, D. G. (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840-844
38. Rajagopalan, S., Kurz, S., Munzel, T. et al. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923
39. Ushio-Fukai, M., Zafari, A. M., Fukui, T., Ishizaka, N. and Griendling, K. K. (1996) p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 271, 23317-23321
40. White, C. R., Darley-Usmar, V., Berrington, W. R. et al. (1996) Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. U.S.A. 93, 8745-8749
41. Vasquez-Vivar, J., Kalyanaraman, B., Martasek, P. et al. (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U.S.A. 95, 9220-9225
42. Warnholtz, A., Nickenig, G., Schulz, E. et al. (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99, 2027-2033
43. Azumi, H., Inoue, N., Takeshita, S. et al. (1999) Expression of NADH/ NADPH oxidase p22phox in human coronary arteries. Circulation 100, 1494-1498
44. Guzik, T. J., West, N. E., Black, E. et al. (2000) Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 86, E85-E90
45. Griendling, K. K., Sorescu, D. and Ushio-Fukai, M. (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494-501
46. Guzik, T. J., Mussa, S., Gastaldi, D. et al. (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656-1662
47. Feng, L., Matsumoto, C., Schwartz, A., Schmidt, A. M., Stern, D. M. and Pile-Spellman, J. (2005) Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 28, 379-384
48. Zou, W., Amcheslavsky, A., Takeshita, S., Drissi, H. and Bar-Shavit, Z. (2005) TNF-α expression is transcriptionally regulated by RANK ligand. J. Cell. Physiol. 202, 371-378
49. Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y. and Yamamoto, H. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275, 25781-25790
50. Yao, J., Mackman, N., Edgington, T. S. and Fan, S. T. (1997) Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κB transcription factors. J. Biol. Chem. 272, 17795-17801
51. Santee, S. M. and Owen-Schaub, L. B. (1996) Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J. Biol. Chem. 271, 21151-21159
52. dela Paz, N. G., Simeonidis, S., Leo, C., Rose, D. W. and Collins, T. (2007) Regulation of NF-κB-dependent gene expression by the POU domain transcription factor Oct-1. J. Biol. Chem. 282, 8424-8434
53. Rimbach, G., Valacchi, G., Canali, R. and Virgili, F. (2000) Macrophages stimulated with IFN-γ activate NF-κB and induce MCP-1 gene expression in primary human endothelial cells. Mol. Cell. Biol. Res. Commun. 3, 238-242
54. Kumar, A., Takada, Y., Boriek, A. M. and Aggarwal, B. B. (2004) Nuclear factor-κB: its role in health and disease. J. Mol. Med. 82, 434-448
55. Bonizzi, G., Bebien, M., Otero, D. C. et al. (2004) Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210
56. Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V. and Karin, M. (2005) IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434, 1138-1143
57. Tran, K., Merika, M. and Thanos, D. (1997) Distinct functional properties of Iκ Bα and Iκ Bβ. Mol. Cell. Biol. 17, 5386-5399
58. Lee, E. G., Boone, D. L., Chai, S. et al. (2000) Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354
59. Russo, G., Leopold, J. A. and Loscalzo, J. (2002) Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vasc. Pharmacol. 38, 259-269
60. Shoelson, S. E., Herrero, L. and Naaz, A. (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180
61. Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G. and Baron, A. D. (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601-2610
62. Cleland, S. J., Petrie, J. R., Ueda, S., Elliott, H. L. and Connell, J. M. (1999) Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension 33, 554-558
63. Jovinge, S.,Hamsten, A., Tornvall, P. et al. (1998) Evidence for a role of tumor necrosis factor α in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metab. Clin. Exp. 47, 113-118
64. Zubelewicz-Szkodzinska, B., Szkodzinski, J., Romanowski, W. et al. (2004) Simvastatin decreases concentration of interleukin-2 in hypercholesterolemic patients after treatment for 12 weeks. J. Biol. Regul. Homeost. Agents 18, 295-301
65. Ascer, E., Bertolami, M. C., Venturinelli, M. L. et al. (2004) Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177, 161-166
66. Marketou, M. E., Zacharis, E. A., Nikitovic, D. et al. (2006) Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 57, 211-218
67. Okopien, B., Krysiak, R., Kowalski, J. et al. (2005) Monocyte release of tumor necrosis factor-α and interleukin-1β in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J. Cardiovasc. Pharmacol. 46, 377-386
68. Zhao, S. P., Wu, Z. H., Wu, J., Hong, S. C. and Deng, P. (2005) Effect of atorvastatin on tumor necrosis factor α serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 46, 185-189
69. Popa, C., Netea, M. G., Radstake, T. et al. (2005) Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 303-305
70. Cauza, E., Cauza, K., Hanusch-Enserer, U., Etemad, M., Dunky, A. and Kostner, K. (2002) Intravenous anti TNF-α antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien. Klin. Wochenschr. 114, 1004-1007
71. Spanakis, E., Sidiropoulos, P., Papadakis, J. et al. (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol. 33, 2440-2446
72. Vis, M., Nurmohamed, M. T., Wolbink, G. et al. (2005) Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32, 252-255
73. Memon, R. A., Grunfeld, C., Moser, A. H. and Feingold, K. R. (1993) Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132, 2246-2253
74. Feingold, K. R., Marshall, M., Gulli, R., Moser, A. H. and Grunfeld, C. (1994) Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler. Thromb. 14, 1866-1872
75. Csiszar, A., Labinskyy, N., Smith, K., Rivera, A., Orosz, Z. and Ungvari, Z. (2007) Vasculoprotective effects of anti-tumor necrosis factor-α treatment in aging. Am. J. Pathol. 170, 388-398
76. Bruunsgaard, H., Skinhoj, P., Pedersen, A. N., Schroll, M. and Pedersen, B. K. (2000) Ageing, tumour necrosis factor-α (TNF-α) and atherosclerosis. Clin. Exp. Immunol. 121, 255-260
77. Belmin, J., Bernard, C., Corman, B., Merval, R., Esposito, B. and Tedgui, A. (1995) Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. Am. J. Physiol. 268, H2288-H2293
78. Csiszar, A., Ungvari, Z., Koller, A., Edwards, J. G. and Kaley, G. (2004) Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol. Genomics 17, 21-30
79. Shimada, Y., Ito, H., Kaji, K. and Fukuda, M. (1990) Tumor necrosis factor reduces lifespan of human endothelial cells in vitro. Mech. Ageing Dev. 55, 245-254
80. Arenas, I. A., Xu, Y. and Davidge, S. T. (2006) Age-associated impairment in vasorelaxation to fluid shear stress in the female vasculature is improved by TNF-α antagonism. Am. J. Physiol. Heart Circ. Physiol. 290, H1259-H1263
81. Giannattasio, C., Zoppo, A., Gentile, G. et al. (2005) Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 25, 406-410
82. Esposito, K., Ciotola, M., Sasso, F. C. et al. (2007) Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-α. Nutr. Metab. Cardiovasc. Dis. 17, 274-279
83. Nappo, F., Esposito, K., Cioffi, M. et al. (2002) Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J. Am. Coll. Cardiol. 39, 1145-1150
84. Fujiyama, Y., Hokari, R., Miura, S. et al. (2007) Butter feeding enhances TNF-α production from macrophages and lymphocyte adherence in murine small intestinal microvessels. J. Gastroenterol. Hepatol. 22, 1838-1845
85. Hennig, B., Toborek, M. and McClain, C. J. (2001) High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J. Am. Coll. Nutr. 20, 97-105
86. Willerson, J. T. and Ridker, P. M. (2004) Inflammation as a cardiovascular risk factor. Circulation 109, II2-II10
87. Bruunsgaard, H. (2005) Physical activity and modulation of systemic low-level inflammation. J. Leukocyte Biol. 78, 819-835
88. Keller, C., Keller, P., Giralt, M., Hidalgo, J. and Pedersen, B. K. (2004) Exercise normalises overexpression of TNF-α in knockout mice. Biochem. Biophys. Res. Commun. 321, 179-182
89. Flynn, M., McFarlin, B. K. and Markofski, M. A. (2007) The anti-inflammatory actions of exercise training. Am. J. Lifestyle Med. 1, 220-235
90. de Lemos, E. T., Reis, F., Baptista, S. et al. (2007) Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type 2) diabetic rats. Med. Sci. Monit. 13, BR168-BR174
91. Das, U. N. (2004) Anti-inflammatory nature of exercise. Nutrition 20, 323-326
92. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110, 1209-1212
93. Iversen, P. O., Woldbaek, P. R., Tonnessen, T. and Christensen, G. (2002) Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R166-R172
94. Rusten, L. S., Smeland, E. B., Jacobsen, F. W. et al. (1994) Tumor necrosis factor-α inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors. J. Clin. Invest. 94, 165-172
95. + myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-κB activation. J. Immunol. 163, 3106-3115
96. -) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-β and TNF-α. J. Immunol. 158, 5169-5177
97. Chen, Y., Ke, Q., Yang, Y. et al. (2003) Cardiomyocytes overexpressing TNF-α attract migration of embryonic stem cells via activation of p38 and c-Jun amino-terminal kinase. FASEB J. 17, 2231-2239
98. Bao, C., Guo, J., Lin, G., Hu, M. and Hu, Z. (2007) TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI. Scand. Cardiovasc. J. 42, 56-62
99. Goukassian, D. A., Qin, G., Dolan, C. et al. (2007) Tumor necrosis factor-α receptor p75 is required in ischemia-induced neovascularization. Circulation 115, 752-762
100. Munker, R., Gasson, J., Ogawa, M. and Koeffler, H. P. (1986) Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 323, 79-82
101. Nishiwaki, Y., Yoshida, M., Iwaguro, H. et al. (2007) Endothelial E-selectin potentiates neovascularization via endothelial progenitor cell-dependent and -independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 27, 512-518
102. Fahlman, C., Jacobsen, F. W., Veiby, O. P., McNiece, I. K., Blomhoff, H. K. and Jacobsen, S. E. (1994) Tumor necrosis factor-α (TNF-α) potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors. Blood 84, 1528-1533
103. Chia, S., Qadan, M., Newton, R., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2003) Intra-arterial tumor necrosis factor-α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 23, 695-701
104. Nakamura, M., Yoshida, H., Arakawa, N., Saitoh, S., Satoh, M. and Hiramori, K. (2000) Effects of tumor necrosis factor-α on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J. Cardiovasc. Pharmacol. 36, 487-492
105. Robinson, S. D., Dawson, P., Ludlam, C. A., Boon, N. A. and Newby, D. E. (2006) Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-α in patients with coronary heart disease. Clin. Sci. 110, 353-360
106. Martens, F. M., Rabelink, T. J., op 't Roodt, J., de Koning, E. J. and Visseren, F. L. (2006) TNF-α induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-γ agonist pioglitazone. Eur. Heart J. 27, 1605-1609
107. Hurlimann, D., Forster, A., Noll, G. et al. (2002) Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187
108. Cardillo, C., Schinzari, F., Mores, N. et al. (2006) Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin. Pharmacol. Ther. 80, 275-281
109. Booth, A. D., Jayne, D. R., Kharbanda, R. K. et al. (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109, 1718-1723
110. Schinzari, F., Armuzzi, A., De Pascalis, B. et al. (2008) Tumor necrosis factor-α antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin. Pharmacol. Ther. 83, 70-76
111. Bilsborough, W., Keen, H., Taylor, A., O'Driscoll, G. J., Arnolda, L. and Green, D. J. (2006) Anti-tumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26, 1125-1131
112. Gonzalez-Juanatey, C., Llorca, J., Sanchez-Andrade, A., Garcia-Porrua, C., Martin, J. and Gonzalez-Gay, M. A. (2006) Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24, 309-312
113. Fichtlscherer, S., Rossig, L., Breuer, S., Vasa, M., Dimmeler, S. and Zeiher, A. M. (2001) Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104, 3023-3025
114. Mann, D. L., McMurray, J. J., Packer, M. et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602
115. Dominguez, H., Storgaard, H., Rask-Madsen, C. et al. (2005) Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42, 517-525
116. Radaelli, A., Loardi, C., Cazzaniga, M. et al. (2007) Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler. Thromb. Vasc. Biol. 27, 2750-2755
117. Sola, S., Mir, M. Q., Lerakis, S., Tandon, N. and Khan, B. V. (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. 47, 332-337
118. Kovacs, I., Toth, J., Tarjan, J. and Koller, A. (2006) Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur. J. Heart Failure 8, 451-459
119. Tikiz, C., Utuk, O., Pirildar, T. et al. (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J. Rheumatol. 32, 2095-2101
120. Tousoulis, D., Antoniades, C., Vassiliadou, C. et al. (2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur. J Heart Failure 7, 1126-1132
121. Koh, K. K., Son, J. W., Ahn, J. Y. et al. (2004) Vascular effects of diet and statin in hypercholesterolemic patients. Int. J. Cardiol. 95, 185-191
122. Economides, P. A., Caselli, A., Tiani, E., Khaodhiar, L., Horton, E. S. and Veves, A. (2004) The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 740-747